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SLC19A2Thiamine-responsive megaloblastic anemia (TRMA) is an autosomal recessive syndrome characterized by
early-onset anemia, diabetes, and hearing loss caused by mutations in the SLC19A2 gene. We studied the ge-
netic cause and clinical features of this condition in patients from the Persian population. A clinical and mo-
lecular investigation was performed in four patients from three families and their healthy family members.
All had the typical diagnostic criteria. The onset of hearing loss in three patients was at birth and one patient
also had a stroke and seizure disorder. Thiamine treatment effectively corrected the anemia in all of our pa-
tients but did not prevent hearing loss. Diabetes was improved in one patient who presented at the age of
8 months with anemia and diabetes after 2 months of starting thiamine. The coding regions of SLC19A2
were sequenced in all patients. The identiﬁed mutation was tested in all members of the families. Molecular
analyses identiﬁed a homozygous nonsense mutation c.697C>T (p.Gln233*) as the cause of the disease in all
families. This mutation was previously reported in a Turkish patient with TRMA and is likely to be a founder
mutation in the Persian population.
© 2013 Elsevier B.V. Open access under CC BY license.1. Introduction
Thiamine-responsive megaloblastic anemia (TRMA, Rogers syn-
drome, OMIM 249270) is a very rare autosomal recessive condition
with childhood onset (Porter et al., 1969). TRMA is characterized by
the clinical triad of megaloblastic anemia, sensorineural hearing loss,
and diabetesmellitus (Neufeld et al., 1997). The other reported features
include visual impairments, congenital heart defects, tri-lineage
myelodysplasia, short stature, and stroke (Bergmann et al., 2009).
TRMA is caused by mutations in the SLC19A2 gene (Neufeld et al.,
1997). This gene is located on chromosome 1q23.3, spanning 6 exons,
and encodes a high-afﬁnity plasma membrane thiamine transporterastic anemia; PCR, polymerase
; MCV, mean corpuscular vol-
re; MPH, mid-parental height.
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hould be considered joint ﬁrst
license.(THTR-1) (Dutta et al., 1999). SLC19A2 is expressed in a wide range of
human tissues including the bone marrow, pancreas, brain, retina,
heart, skeletal muscle, kidney, liver, lung, small intestine, colon, placen-
ta, lymphocytes and ﬁbroblasts (Fleming et al., 1999). Using mouse
models, it has been recently demonstrated that THTR1 along with
THTR2 are involved in carrier-mediated thiamine uptake by pancreatic
acinar cells (Subramanian et al., 2012). In human, SLC19A2 has been
shown to encode the sole thiamine transporter in bone marrow, a sub-
set of cochlear cells, and pancreatic beta cells (Oishi et al., 2012).
SLC19A2 mutations result in thiamine deﬁciency in pancreatic beta
cells and other affected tissues, leading to defects in cellular metabo-
lism, cell stress, and apoptosis (Oishi et al., 2012). High dose thiamine
therapy in TRMA patients can improve the disease symptoms,
correcting the anemia and reducing or cessating the need for exogenous
insulin (Alzahrani et al., 2006; Porter et al., 1969). Liberman et al.
(2006) demonstrated that, in mice, deletion of SLC19A2 results in selec-
tive loss of inner hair cells of cochlea and leads to auditory neuropathy
phenotype. It has been suggested that thiamine supplementationmight
prevent sensorineural hearing loss in children if started before two
months of age (Onal et al., 2009).
We investigated the genetic basis of the diseases in four new cases
of TRMA from the Persian population.
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2.1. Families and patients
We studied three Persian families with TRMA. Two families were
consanguineous (ﬁrst cousins) whereas the third family (with two af-
fected siblings) was non-consanguineous. The diagnosis was made
based on the presence of megaloblastic anemia, sensorineural deaf-
ness, and diabetes mellitus.
Written informed consent for clinical and molecular investigation
was obtained from all members of the families or their legal guardians.
The study was conducted in accordance with the Helsinki Declaration.2.2. Methods
Genomic DNA was extracted from peripheral blood using QIAamp
DNA blood Midi kits (Qiagen, Hilden, Germany). The exons and in-
tron–exon boundaries of SLC19A2 were ampliﬁed using polymerase
chain reaction (PCR). Unidirectional sequencing was carried out using
standardmethods on anABI 3730 sequencer (Applied Biosystems,War-
rington, UK). The resulting DNA sequence was analyzed with Mutation
Surveyor software (version 3.20; SoftGenetics, State College, PA) and
against the reference sequence (accession number NM_006996.2).
The other family members were screened for the identiﬁedmutation.Table 1
Clinical and hematological details of TRMA patients.
P-1 (female) P-2 (male)
Age (at last visit) 2 y 24 y
Consanguinity + −
The ﬁrst complaints Pallor, polyurea, polydipsia Anemia
Onset age of anemia 8 m 3 m
Onset age of deafness 10 m Congenital
Onset age of diabetes 8 m 16 m
Hemoglobin (g/dL) F: 5.6
L (16 m later): 13.4
F: 8.1
L (23 y later
MCV F: 100
L: 101.7
F: 101
L: 100
Reticulocyte count (%)
(n~0.5%–2%)
0.4 0.6
Platelet count F: 30,000
L: 266,000 (16 m later)
(thrombocytopenia)
214,000
WBC (/mm3) 4800 6400
Weight (centile) (5th) (5th)
Height (centile) SDS: −2.3 SDS: −2.18
Seizures − +
Stroke − +
Transfusion dependent before thiamine
therapy
One episode of transfusion +
Transfusion dependent after thiamine
therapy
− −
Thiamine dose (mg) 100 300
Peripheral smear Macrocytosis, anisocytosis,
target cells
Macrocytosis
Bone marrow aspirate Normocellular, megaloblastic
change
Megaloblasti
Serum folate concentration (ng/mL)
(n>2.5 ng/mL)
? 12.5
Vitamin B12 (pg/mL)
(n~140–700 pg/mL)
? 870
Ferritin (ng/mL) ? 1100
(due to repe
transfusion)
HbA1c at the last visit
Nlb6%
5.9% (2 y) 8.6% (24 y)
MCV: mean corpuscular volume, WBC: white blood cell, SDS: standard deviation score, MPH
−: absence of condition, ?: unknown, F: ﬁrst visit, L: last visit.3. Results
3.1. Clinical investigation
We identiﬁed four patients from three unrelated families. Two
families were consanguineous (ﬁrst cousins) but the third family, with
two affected siblings (P-2 and P-3), was non-consanguineous. The clin-
ical details are summarized in Table 1. All our patients presented with
early onset anemia, hearing loss, and diabetes. Three of the patients
(P2–4) presenting with anemia (with onset ages of 3 m, 1 y, and 5 y)
were transfusion dependent without any precise diagnosis when their
diabetes was diagnosed. The patients were born after uneventful and
full-term pregnancies. The hearing problem started from infancy
when their parents noted they showed no response to sounds. All
parents were healthy.
On physical examination, all patients were pale and of short-stature,
whereas their parents andhealthy siblings had normal stature. Examina-
tions of the heart, lungs, eyes, kidneys and liver were normal. Brainstem
audiometry revealed sensorineural hearing loss in all patients.
The important laboratory ﬁndings included decreased hematocrit
and hemoglobin levels, and elevated random serum glucose and
fasting serum glucose levels in all probands. Serum creatinine, elec-
trolytes, ferritin, folic acid and B12 levels, urea nitrogen, and liver
enzymes were within normal ranges in all patients. The patient had
normal serum amino acid levels and no aminoaciduria was detected.P-3 (female) P-4 (male)
28 y 13.5 y
− +
Anemia Anemia
1 y 5 y
Congenital Congenital
2 y 7 y
): 13.8
F:5
L (27 y later): 12.7
F: 7.5
L (8.5 y later): 13.4
F: 106.9
L: 102
F: 102
L: 102
1.4 1.2
320,000 284,000
6700 8600
(5th) (10th)
SDS: −3.3 (10–25th)
SDS: −2.5
(corrected for the MPH)
− −
− −
+ +
− −
300 100
Macrocytosis Hypochromia, anisocytosis,
macrocytosis
c anemia Hypocellular marrow with
macrocytosis
Normocellular with macrocytosis
7.2 8.9
381 612
ated
87 112
7% (28 y) 8.5% (13.5 y)
: mid-parental height, NA: not applicable, Y: years, M: month, +: presence of condition,
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counts in other probands were within normal ranges.
The peripheral blood smear demonstrated predominance of macro-
cytic cells with no hemolytic ﬁndings such as fragments or spherocytes.
Bone marrow aspiration was performed and histopathological study of
the specimens revealed megaloblastic changes, abnormal erythropoie-
sis and normal cellularity, except in P-3 that showed hypocellularity.
One of the patients, P-2, had history of stroke and several seizures.
The electroencephalogram, at the age of 2 years, was suggestive of
focal epilepsy. His ischemic stroke at 16 months, and in presence of
diabetic ketoacidosis, resulted in left hemiparesis. CT-scan and lum-
bar puncture were normal.
Based on clinical, including anemia and deafness, and paraclinical
ﬁndings, TRMA was diagnosed and insulin therapy was started to
correct the hyperglycemia. The treatment of patientswith oral thiamine
hydrochloride was remarkably effective in correction of anemia, and
hemoglobin and hematocrit increased to normal levels within a few
weeks; however no improvement in MCV values was observed
(Table 1). The thrombocytopenia of P-1 was corrected. Thiamine treat-
ment did not improve the hearing problem in any of our patients, but
improved diabetes in P-1 after 2 months and therefore insulin was
stopped. At the age of 24 months, HbA1C level was normal (5.9%).
3.2. Molecular analysis
Molecular study of the SLC19A2 gene in the four probands revealed
that all were homozygous for a nonsense mutation, c.697C>T
(p.Gln233*), in the second exon. This mutation substitutes glutamine at
position 233 for a stop codon, predicted to cause truncation of THTR1
and/or nonsense mediated decay of the SLC19A2messenger RNA.
All the obligate carrier parents were conﬁrmed as heterozygous
for the nonsense mutation.
4. Discussion
We identiﬁed a homozygous nonsense mutation in SLC19A2 in a
series of four TRMA patients from three unrelated Persian families.
Mutation c.697C>T, alters the amino acid glutamine at residue 233 to
a stop codon. This mutation was previously described in a 5 year old
male patient from a non-consanguineous Turkish family (Ozdemir et
al., 2002). To date, only four SLC19A2 mutations have been identiﬁed
in multiple families, of which only two (c.484C>T and c.515G>A)
were present in more than one ethnicity (Bergmann et al., 2009).
Three of the 4 patients had short stature. The etiology of short
stature is unclear because further workup including the evaluation
of GH–IGF-I axis was not done. Thiamine therapy, however, did not
improve growth of those patients.
Interestingly, hearing loss was the ﬁrst recognized feature and was
present at birth in three of four patients reported in this study, whereas
no congenital hearing loss in TRMA has been reported in the literature,
to our knowledge. Thiamine started at the age of 8 months did not pre-
vent hearing loss in P-1 (Table 1), contrary to previous reports (Onal et
al., 2009), but did improve blood sugar levels.
Signiﬁcant neurocognitive deﬁcits, stroke and seizure, were present
in one of our patients, P-2, but other cases and the Turkish patient did
not report similar history. His stroke, at 16 months of age, was ischemic
and resulted in left hemiparesis. Stroke is a sparse feature in TRMA,
reported in only a few cases, of which, only in one case genetic study
was performed, revealing a nonsense mutation, G152*, as the cause of
the disease (Bergmann et al., 2009). His seizures occurred in the ab-
sence of hypoglycemia, and EEG evaluations at the age of 2 years re-
vealed focal epilepsy. Seizure has been reported only in 5 TRMA cases.
To our knowledge, this is the ﬁrst report of a TRMA case with coexis-
tence of stroke and seizure disorder.
Ricketts et al. investigated 13 patients and had follow-up data for a
median of 9 years (2–30 y) (Ricketts et al., 2006). They reported thatalmost all patients became transfusion dependent in adulthood, despite
the initial improvement of their hemoglobin in answer to thiamine
therapy, suggesting puberty as determinant of deteriorating the meta-
bolic control. On contrary, all our patients maintained a good response
to thiamine therapy, their hemoglobin and hematocrit levels remained
within the normal ranges, and they did not become transfusion depen-
dent in adulthood even several years after puberty (P-2 and P-3).
Early treatmentwith thiamine can improve diabetes in TRMA, as ob-
served in one of our cases (P-1) and the Turkish patient. Blood sugar
levels of P-1 were controlled after 2 months of treatment with thia-
mine, and insulin was discontinued. Treatment outcomes in this case
and other Turkish patient suggest that early commencement of thia-
minemay improve diabetes. In late diagnosed cases, like our other 3 pa-
tients, the control of diabetes depends on the compliance of patients.
We identiﬁed a nonsense mutation, c.697C>T (p.Gln233*), in
SLC19A2 in a series of TRMA patients with congenital/early neonatal
hearing loss and neonatal/early childhood diabetes and anemia. These
ﬁndings conﬁrm that TRMA should be considered in the differential di-
agnosis of neonatal/early childhood hearing loss, megaloblastic anemia
of unknown cause, and diabetes. Childhoodmegaloblastic anemiawith-
out folic acid or vitamin B12 deﬁciency should also raise the possibility
of TRMA. We suggest that early onset of thiamine can improve or pre-
vent diabetes in patients with TRMA. The results of this study expand
the current knowledge on genotype–phenotype correlations in
SLC19A2 and have applications in screening and genetic counseling.
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